Prostate cancer: is androgen-deprivation therapy chosen wisely?
- PMID: 25073003
- DOI: 10.1038/nrclinonc.2014.130
Prostate cancer: is androgen-deprivation therapy chosen wisely?
Comment on
-
Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.JAMA Intern Med. 2014 Sep;174(9):1460-7. doi: 10.1001/jamainternmed.2014.3028. JAMA Intern Med. 2014. PMID: 25023796 Free PMC article.
Similar articles
-
Primary androgen deprivation therapy in men with prostate cancer.JAMA. 2009 Jan 7;301(1):35; author reply 35. doi: 10.1001/jama.2008.903. JAMA. 2009. PMID: 19126809 No abstract available.
-
Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data.JAMA Intern Med. 2014 Sep;174(9):1468-9. doi: 10.1001/jamainternmed.2014.1107. JAMA Intern Med. 2014. PMID: 25023522 No abstract available.
-
Prostate cancer: Say no to ADT for localized disease.Nat Rev Urol. 2014 Sep;11(9):487. doi: 10.1038/nrurol.2014.187. Epub 2014 Jul 29. Nat Rev Urol. 2014. PMID: 25069734 No abstract available.
-
Hormone-refractory prostate cancer: what have we learned?BJU Int. 2007 Jul;100 Suppl 2:56-9. doi: 10.1111/j.1464-410X.2007.06957.x. BJU Int. 2007. PMID: 17594362 Review. No abstract available.
-
Hormone therapy in advanced prostate cancer.Front Radiat Ther Oncol. 2002;36:49-65. doi: 10.1159/000061329. Front Radiat Ther Oncol. 2002. PMID: 11842755 Review. No abstract available.
Cited by
-
A Multifunctional LNA Oligonucleotide-Based Strategy Blocks AR Expression and Transactivation Activity in PCa Cells.Mol Ther Nucleic Acids. 2020 Oct 27;23:63-75. doi: 10.1016/j.omtn.2020.10.032. eCollection 2021 Mar 5. Mol Ther Nucleic Acids. 2020. PMID: 33335793 Free PMC article.
References
-
- JAMA Intern Med. 2014 Sep;174(9):1460-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical